1-(3-氯苯基)-4-哌啶酮 | 115012-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(3-氯苯基)-4-哌啶酮
• 英文名称: 1-(3-Chlorophenyl)piperidin-4-one
• CAS: 115012-58-3
• 化学式: C₁₁H₁₂ClNO
• 分子量: 209.675
• InChiKey: JJYTZAMHBNGTOX-UHFFFAOYSA-N

物化性质

• 沸点：
  361.2±37.0 °C(Predicted)
• 密度：
  1.232±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-(3-氯苯基)-4-哌啶酮 、 苄叉丙酮 在 L-脯氨酸 作用下， 以 乙醇 为溶剂， 反应 48.0h， 以79%的产率得到3-(3-chlorophenyl)-6-hydroxy-6-methyl-8-phenyl-3-azabicyclo[3.3.1]nonan-9-one
  参考文献：
  名称：

  （l）-脯氨酸催化的1-取代的哌啶-4-酮与（E）-4-芳基丁-3-烯-2-酮的新型串联反应：N-取代基介导的产物选择性和新型氮杂环的合成

  摘要：

  （l）-脯氨酸催化的1-烷基/芳烷基哌啶-4-酮与（E）-4-芳基丁-3-烯-2-酮的反应提供了具有两个或三个环的新型异喹啉衍生物，串联反应收率很高罗宾逊环化–迈克尔加成序列，而1-芳基哌啶-4-酮与（E）-4-芳基丁-3-烯-2-酮的反应生成3-氮杂双环[3.3.1]壬南-9-通过串联的迈克尔加成-醛醇缩合反应序列得到。

  DOI：

  10.1016/j.tet.2007.01.038
• 作为产物：
  描述：

  N-苄基哌啶酮 在 potassium carbonate 作用下， 以 乙醇 、 水 、 丙酮 为溶剂， 反应 3.75h， 生成 1-(3-氯苯基)-4-哌啶酮
  参考文献：
  名称：

  A Convenient Synthesis to N-Aryl-Substituted 4-Piperidones

  摘要：

  [GRAPHICS]A general and efficient procedure for the synthesis of N-aryl-substituted 4-piperidones was developed. The general methodology was applied to the synthesis of several different N-aryl-4-piperidones utilizing an expedient two-step process.

  DOI：

  10.1021/ol990930r

文献信息

• Some observations relating to the use of 1-aryl-4-alkoxypiperidin-4-yl groups for the protection of the 2′-hydroxy functions in the chemical synthesis of oligoribonucleotides
  作者：Wayne Lloyd、Colin B. Reese、Quanlai Song、Anthony M. Vandersteen、Cristina Visintin、Pei-Zhou Zhang

  DOI：10.1039/a908149f

  日期：——

  The comparative rates of acid-catalysed removal of ten 1-aryl-4-methoxypiperidin-4-yl 8 (R = Me) [including the previously reported Ctmp 5 and Fpmp 6] protecting groups for the 2′-hydroxy functions in oligoribonucleotide synthesis are discussed. These studies have led to the development of the 1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl (Cpep) protecting group 8 (R = Et, R1 = R2 = H, R3 = Cl) which is both more stable than the Ctmp and Fpmp groups at pH 0.5 and more labile at pH 3.75. The influence of the ribonucleoside aglycone on the stability of the 2′-O-Fpmp and 2′-O-Ctmp protecting groups both at low and high pH is examined.

  讨论了在寡核苷酸合成中，十个1-芳基-4-甲氧基哌啶-4-基（R = Me，包括先前报道的Ctmp 5和Fpmp 6）保护基对2'-羟基功能的酸催化去除的相对速率。这些研究导致开发了1-(4-氯苯基)-4-乙氧基哌啶-4-基（Cpep）保护基8（R = Et，R1 = R2 = H，R3 = Cl），其在pH 0.5下比Ctmp和Fpmp群更加稳定，而在pH 3.75下更加不稳定。研究了核苷酸基在低pH和高pH下对2'-O-Fpmp和2'-O-Ctmp保护基稳定性的影响。
• Synthesis of Substituted<i>N</i>-Arylpiperidines via Organobismuth Derivatives
  作者：Aldo Banfi、Marcella Bartoletti、Elio Bellora、Maura Bignotti、Marco Turconi

  DOI：10.1055/s-1994-25569

  日期：——

  The synthesis of N-arylpiperidines functionalized both on the aromatic and piperidine ring was performed using conveniently substituted triarylbismuthine derivatives as arylating agents. This method is, in particular, indicated to arylate the nitrogen atom of a secondary amine with a phenyl ring bearing electron-withdrawing groups in the m-position.

  使用方便取代的三芳基铋衍生物作为芳基化剂合成在芳香环和哌啶环上均官能化的N-芳基哌啶。该方法特别表明用在间位带有吸电子基团的苯环芳基化仲胺的氮原子。
• Compounds useful as antagonists of CCR2
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US08067457B2

  公开（公告）日：2011-11-29

  The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.

  本发明提供了通式I的化合物：或其药学上可接受的盐，其中X，n，Y和R1在此总体上和子集中被定义。本发明的化合物是CCR2的抑制剂，因此可用于治疗各种炎症、过敏和自身免疫性疾病、疾病或病况。
• COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2
  申请人：Ghosh Shomir

  公开号：US20120214807A1

  公开（公告）日：2012-08-23

  The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R 1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.

  本发明提供了一般式I的化合物：或其药学上可接受的盐，其中X，n，Y和R1在此总体上和子集中被定义。本发明的化合物是CCR2的抑制剂，因此可用于治疗各种炎症、过敏和自身免疫性疾病、障碍或病况。
• VOLTAGE-GATED SODIUM CHANNEL BLOCKERS
  申请人：Boehm Jeffrey Charles

  公开号：US20130023541A1

  公开（公告）日：2013-01-24

  The present invention relates to voltage-gated sodium channel blocker intermediates, compounds and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory or respiratory tract diseases.

  本发明涉及电压门控钠通道阻滞剂中间体、化合物和二聚体，相应的药物组合物、化合物制备和治疗呼吸或呼吸道疾病的方法。